CDK2 inhibitors that we previously identified in similar screens also showed protection in postmitotic cochlear cells whereas both BRAF inhibitors and CDK2 inhibitors are two known groups of anti-proliferative compounds in tumor cells (13, 34). Here, CDK2 is linked to neoplasm.